Paxton Secures $41.5M from Pfizer & Tris Pharma for Providing Adulterated Drugs to Children

Translate to Spanish or other 102 languages!

Following Attorney General Paxton’s lawsuit, Pfizer and Tris Pharma have agreed to pay $41.5 million and ensure that they follow all state and federal laws related to the manufacturing and distribution of drugs. Image for illustration purposes
- Advertisement -

AUSTIN – Attorney General Ken Paxton has secured a $41.5 million settlement with Pfizer and Tris Pharma for allegedly providing adulterated pharmaceutical drugs to Texas children in violation of the Texas Health Care Program Fraud Prevention Act (“THFPA”).    

“I will never back down from taking on the biggest corporations in the world that deceive and take advantage of Texans. Pfizer and Tris Pharma provided adulterated drugs to children for years and changed test results in order to obtain the benefit of taxpayer-funded Medicaid reimbursement,” said Attorney General Paxton. “Under my watch, Big Pharma will not escape justice for lying about the effectiveness of its drugs.”  

In November 2023, Attorney General Paxton sued Pfizer and Tris Pharma, alleging that the pharmaceutical companies had knowingly provided an ADHD medication named Quillivant XR to children on Medicaid despite the drug’s pattern of failing quality control tests due to flawed manufacturing practices. The lawsuit alleged that from 2012 to 2018, Pfizer and Tris altered the drug’s testing method in violation of federal and state laws to ensure Quillivant satisfied regulatory hurdles and could continue to be sold.   

- Advertisement -

Following Attorney General Paxton’s lawsuit, Pfizer and Tris Pharma have agreed to pay $41.5 million and ensure that they follow all state and federal laws related to the manufacturing and distribution of drugs.  

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Lab-Grown Mini Organs Show Promise in Predicting Breast Cancer Treatment Outcomes

Researchers at UC San Francisco have developed a new method to predict how different types of breast cancer will respond to treatment, using patient data from the I-SPY2 breast cancer trial and rapid testing on lab-grown mini tumors. 

STHS Hosting Community Blood Drive Amid National Blood Shortage, August 21st 

The United States is facing a severe blood shortage, prompting the American Red Cross to issue only the second national blood crisis declaration in its history.

DHR Health Recertified for Advanced Hip & Knee Replacements

DHR Health has once again earned The Joint Commission's Advanced Certification in Total Hip and Total Knee Replacement, reaffirming its commitment to providing high-quality, patient-centered orthopedic care to the Rio Grande Valley.

STHS Named to Newsweek’s America’s Greatest Midsize Workplaces for Women

The American workforce is more diverse than ever, with women helping lead that transformation. 
- Advertisement -